Protease inhibitors do not affect antibody responses to pneumococcal vaccination

Indhira De La Rosa, Iona M. Munjal, Maria Rodriguez-Barradas, Xiaoying Yu, Liise Anne Pirofski, Daniel Mendoza

Research output: Contribution to journalArticle

Abstract

HIV+ subjects on optimal antiretroviral therapy have persistently impaired antibody responses to pneumococcal vaccination. We explored the possibility that this effect may be due to HIV protease inhibitors (PIs). We found that in humans and mice, PIs do not affect antibody production in response to pneumococcal vaccination.

Original languageEnglish (US)
Pages (from-to)524-529
Number of pages6
JournalClinical and Vaccine Immunology
Volume23
Issue number6
DOIs
StatePublished - Jun 1 2016
Externally publishedYes

Fingerprint

Protease Inhibitors
Antibody Formation
Vaccination
HIV Protease Inhibitors
Antibodies
HIV
DegP protease
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Cite this

De La Rosa, I., Munjal, I. M., Rodriguez-Barradas, M., Yu, X., Pirofski, L. A., & Mendoza, D. (2016). Protease inhibitors do not affect antibody responses to pneumococcal vaccination. Clinical and Vaccine Immunology, 23(6), 524-529. https://doi.org/10.1128/CVI.00026-16

Protease inhibitors do not affect antibody responses to pneumococcal vaccination. / De La Rosa, Indhira; Munjal, Iona M.; Rodriguez-Barradas, Maria; Yu, Xiaoying; Pirofski, Liise Anne; Mendoza, Daniel.

In: Clinical and Vaccine Immunology, Vol. 23, No. 6, 01.06.2016, p. 524-529.

Research output: Contribution to journalArticle

De La Rosa, I, Munjal, IM, Rodriguez-Barradas, M, Yu, X, Pirofski, LA & Mendoza, D 2016, 'Protease inhibitors do not affect antibody responses to pneumococcal vaccination', Clinical and Vaccine Immunology, vol. 23, no. 6, pp. 524-529. https://doi.org/10.1128/CVI.00026-16
De La Rosa, Indhira ; Munjal, Iona M. ; Rodriguez-Barradas, Maria ; Yu, Xiaoying ; Pirofski, Liise Anne ; Mendoza, Daniel. / Protease inhibitors do not affect antibody responses to pneumococcal vaccination. In: Clinical and Vaccine Immunology. 2016 ; Vol. 23, No. 6. pp. 524-529.
@article{2abcfb37352d440786bdd8b26800e814,
title = "Protease inhibitors do not affect antibody responses to pneumococcal vaccination",
abstract = "HIV+ subjects on optimal antiretroviral therapy have persistently impaired antibody responses to pneumococcal vaccination. We explored the possibility that this effect may be due to HIV protease inhibitors (PIs). We found that in humans and mice, PIs do not affect antibody production in response to pneumococcal vaccination.",
author = "{De La Rosa}, Indhira and Munjal, {Iona M.} and Maria Rodriguez-Barradas and Xiaoying Yu and Pirofski, {Liise Anne} and Daniel Mendoza",
year = "2016",
month = "6",
day = "1",
doi = "10.1128/CVI.00026-16",
language = "English (US)",
volume = "23",
pages = "524--529",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Protease inhibitors do not affect antibody responses to pneumococcal vaccination

AU - De La Rosa, Indhira

AU - Munjal, Iona M.

AU - Rodriguez-Barradas, Maria

AU - Yu, Xiaoying

AU - Pirofski, Liise Anne

AU - Mendoza, Daniel

PY - 2016/6/1

Y1 - 2016/6/1

N2 - HIV+ subjects on optimal antiretroviral therapy have persistently impaired antibody responses to pneumococcal vaccination. We explored the possibility that this effect may be due to HIV protease inhibitors (PIs). We found that in humans and mice, PIs do not affect antibody production in response to pneumococcal vaccination.

AB - HIV+ subjects on optimal antiretroviral therapy have persistently impaired antibody responses to pneumococcal vaccination. We explored the possibility that this effect may be due to HIV protease inhibitors (PIs). We found that in humans and mice, PIs do not affect antibody production in response to pneumococcal vaccination.

UR - http://www.scopus.com/inward/record.url?scp=84973473369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973473369&partnerID=8YFLogxK

U2 - 10.1128/CVI.00026-16

DO - 10.1128/CVI.00026-16

M3 - Article

AN - SCOPUS:84973473369

VL - 23

SP - 524

EP - 529

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 6

ER -